Frankfurt
03.10.25 | 08:05
14,720 Euro
-4,29 % -0,660
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.09. | Nomination Committee of XVIVO Perfusion AB | 200 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / September 5, 2025 / The following members have been appointed to XVIVO Perfusion's (STO:XVIVO)(LSE:0RKL)(FRA:3XV) nomination committee for the 2026 annual general... ► Artikel lesen | |
| 28.07. | XVIVO Perfusion AB: Delay in CE Approval for XVIVO's Perfusion Solution for Heart Preservation | 457 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / July 28, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV). The XVIVO Heart Assist Transport and the XVIVO Heart Assist Transport Perfusion Set have received... ► Artikel lesen | |
| 22.07. | Xvivo enrolls first patient in Heart Assist Transport device study | 2 | MassDevice | ||
| 21.07. | XVIVO Perfusion AB: First Patient Enrolled in US PRESERVE CAP Study for XVIVO Heart Assist Transport Device | 274 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / July 21, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Today, XVIVO announces that the first patient has been enrolled as part of the Continued Access... ► Artikel lesen | |
| XVIVO PERFUSION Aktie jetzt für 0€ handeln | |||||
| 11.07. | XVivo Q2 2025: Umsatzrückgang lässt Aktie einbrechen | 21 | Investing.com Deutsch | ||
| 11.07. | XVIVO Perfusion AB: Interim Report January-June 2025 | 310 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / July 11, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)A quarter showing a mixed pictureSecond quarter 2025 (Apr-Jun)• Net sales amounted to SEK 178.3 million... ► Artikel lesen | |
| 11.07. | Marktgegenwind bremst XVIVO: Organisches Wachstum im zweiten Quartal um 11 % rückläufig | 4 | Investing.com Deutsch | ||
| 11.07. | XVIVO Q2 2025 slides reveal -11% organic growth amid market headwinds | 2 | Investing.com | ||
| 10.07. | XVIVO Perfusion AB: Conference Call on Interim Report April-June 2025 | 338 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / July 10, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report April-June 2025. The... ► Artikel lesen | |
| 13.06. | XVIVO Perfusion AB: XVIVO Honored with 2025 SACC-USA Business Award for Life-Saving Innovation and Growth in the U.S. Market | 294 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / June 13, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Yesterday, XVIVO received the prestigious Swedish American Chamber of Commerce USA (SACC-USA)... ► Artikel lesen | |
| 29.04. | XVIVO Perfusion AB: XVIVO Presents 12-Month Follow-Up Results from European Multicenter Heart Transplantation Trial at ISHLT in Boston | 318 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 29, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - The 12-month follow-up results from XVIVO's European multicenter heart trial, NIHP2019, was presented... ► Artikel lesen | |
| 25.04. | Bulletin from Annual General Meeting in XVIVO Perfusion AB | 373 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / April 25, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)The following resolutions were passed at the Annual General Meeting (the "AGM") of XVIVO Perfusion... ► Artikel lesen | |
| 24.04. | XVIVO Perfusion AB: Interim Report January-March 2025 | 275 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 24, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)First quarter 2025 (Jan-Mar)Net sales increased to SEK 218.6 million (186.0), corresponding to growth... ► Artikel lesen | |
| 15.04. | XVIVO Perfusion AB: Conference Call on Interim Report January-March 2025 | 393 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 15, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report January-March 2025.... ► Artikel lesen | |
| 02.04. | XVIVO Perfusion AB: Annual Report 2024 | 354 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 2, 2025 / XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL) (FRA:3XV)Today XVIVO Perfusion AB (publ) publish the Annual Report for 2024. The Annual Report is attached... ► Artikel lesen | |
| 20.03. | Notice to Attend the Annual General Meeting in XVIVO Perfusion AB | 346 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / March 20, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) (publ) (the "Company"), reg. no. 556561-0424, with its registered office in Mölndal, gives notice... ► Artikel lesen | |
| 28.01. | XVIVO Perfusion AB: Year-End Report 2024 | 323 | ACCESS Newswire | GOTHENBURG, SE / ACCESSWIRE / January 28, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Fourth quarter 2024 (October 1 - December 31)• Net sales amounted to SEK 227.6 million (155.7), corresponding... ► Artikel lesen | |
| 13.01. | XVIVO Perfusion AB: Conference Call on Year-End Report 2024 | 423 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESSWIRE / January 13, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Invitation to attend XVIVO's conference call regarding the presentation of the Year-end Report... ► Artikel lesen | |
| 26.11.24 | XVIVO Perfusion AB: Enrollment Completed Five Months Early in the US Clinical Trial Evaluating XVIVOs Heart Preservation Technology | 433 | ACCESS Newswire | GOTHENBURG, SE / ACCESSWIRE / November 25, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) XVIVO's innovative heart technology is currently under investigation in the US clinical trial "PRESERVE:... ► Artikel lesen | |
| 14.11.24 | XVIVO Perfusion AB: XVIVO Perfusion Appoints Lena Hagman as Deputy CEO | 315 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESSWIRE / November 14, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) The Board of Directors of XVIVO Perfusion AB (publ) ("XVIVO") has today appointed Lena Hagman... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 18,000 | +1,75 % | Eckert & Ziegler mit EILMELDUNG: Könnte die Aktie jetzt komplett drehen - Experten warnen! | ||
| UNITEDHEALTH | 306,10 | -0,15 % | 3 Charts in 3x33 Sekunden - Heute mit NVIDIA, UnitedHealth Group und Palladium | Willkommen zu '3 Charts in 33 Sekunden'! Jörg Scherer stellt uns drei Charts vor, die er aktuell ganz besonders unter die Lupe nimmt. Welche Ziele oder Signale jetzt wichtig sind, erfahren Sie im Video!... ► Artikel lesen | |
| INTUITIVE SURGICAL | 388,25 | +0,37 % | Opening Bell: Puma, Novo Nordisk, Droneshield, Rio Tinto, Robinhood, Intuitive Surgical | In den USA droht ein Government Shutdown: Republikaner und Demokraten blockieren die Übergangsfinanzierung, zusätzliche Marktrisiken entstehen.Novo Nordisk wagt den zweiten Anlauf zur US-Zulassung von... ► Artikel lesen | |
| RHOEN-KLINIKUM | 11,700 | +0,86 % | RHÖN-KLINIKUM Campus Bad Neustadt erneut als Schwerpunktzentrum Hypertonie zertifiziert | Bad Neustadt a.d. Saale (ots) - Die Klinik für kardiologische Rehabilitation am RHÖN-KLINIKUM Campus Bad Neustadt wurde erneut von der Deutschen Hochdruckliga e. V. (DHL®) als "Schwerpunktzentrum Hypertonie"... ► Artikel lesen | |
| HIMS & HERS HEALTH | 46,170 | -0,04 % | Why Hims & Hers Stock Slipped Today | ||
| BICO GROUP | 1,965 | +0,26 % | BICO Group AB: Maria Rankka appointed Board Chair of BICO Group AB | The Board of Directors has with immediate effect among its members elected Maria Rankka to serve as Board Chair of BICO Group AB, until a new chair has been elected by the shareholders' meeting. Maria... ► Artikel lesen | |
| M1 KLINIKEN | 14,100 | -0,70 % | M1 Kliniken: Beauty-Sparte treibt den Gewinn | Die M1 Kliniken AG hat im ersten Halbjahr 2025 den Gewinn deutlich ausgebaut. Der Konzernumsatz stieg um 9,4 Prozent auf 183,5 Millionen Euro nach 167,7 Millionen Euro im Vorjahreszeitraum. Das EBIT... ► Artikel lesen | |
| BAXTER | 20,500 | +0,44 % | Dividendenbekanntmachungen (29.08.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACNB CORPORATION US0008681092 0,34 USD 0,2911 EUR ADVANCED DRAINAGE SYSTEMS INC US00790R1041 0,18 USD 0,1541 EUR AEBI SCHMIDT HOLDING... ► Artikel lesen | |
| JD HEALTH INTERNATIONAL | 7,250 | +1,40 % | Aktie von JD Health büßt 2,73 Prozent ein (7,125 €) | An der Börse notiert die JD Health-Aktie zur Stunde ein wenig leichter. Zuletzt zahlten Investoren für die Aktie 7,13 Euro. Die Aktie von JD Health verzeichnet gegenwärtig einen Kursrückgang von 2,73... ► Artikel lesen | |
| LIFEWARD | 0,770 | -0,82 % | Lifeward Ltd.: Lifeward Achieves CE Mark Approval for the ReWalk 7 Personal Exoskeleton | MARLBOROUGH, Mass. and YOKNEAM ILLIT, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform... ► Artikel lesen | |
| COOPER COMPANIES | 60,00 | -0,83 % | Cooper Companies-Aktie verliert 5,17 Prozent (55,00 €) | Die Aktie von Cooper Companies notiert am Dienstag leichter. Zuletzt zahlten Investoren für die Aktie 55,00 Euro. Für Inhaber von Cooper Companies ist der heutige Handelstag bisher nicht sonderlich... ► Artikel lesen | |
| SURGICAL SCIENCE SWEDEN | 8,240 | +0,18 % | Surgical Science Sweden AB: Sales in the second quarter were weak, which together with large currency effects weighed on the result | According to the preliminary reporting, Surgical Science's sales for the second quarter amounted to approximately SEK 209 million, a decrease of 2% compared to the second quarter of 2024. For the various... ► Artikel lesen | |
| PERSPECTIVE THERAPEUTICS | 2,960 | -4,52 % | Perspective Therapeutics, Inc.: Perspective Therapeutics Announces First Patient Dosed with PSV359 in the Second Cohort of a Phase 1/2a Study in Patients with FAP-a Positive Solid Tumors | SEATTLE, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatments... ► Artikel lesen | |
| COMMUNITY HEALTH SYSTEMS | 2,540 | -3,05 % | Community Health Systems engagiert scheidenden CEO als Berater | ||
| SOLENO THERAPEUTICS | 49,240 | -2,98 % | Piper Sandler bestätigt "Overweight"-Rating für Soleno Therapeutics und sieht Kaufgelegenheit |
XVIVO PERFUSION AB gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von -0,660 (-4,29 %) liegt der Kurs bei 14,720 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XVIVO PERFUSION AB finden Sie auf Wallstreet Online.